Chemoprevention against hepatocellular carcinoma

Clinical Journal of Gastroenterology

Volumn 4, Issue 4, 2011, Pages 185-197

  Okano, Jun Ichi ^a   Fujise, Yuki ^a   Abe, Ryo ^a   Imamoto, Ryu ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Chemoprevention; Hepatocellular carcinoma; Phytochemicals

Indexed keywords

ACYCLIC RETINOID; ALLYL SULFIDE; ANTINEOPLASTIC AGENT; CAFESTOL; CAFFEINE; CAPSAICIN; CEPHARANTHINE; CINNAMALDEHYDE; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIGALLOCATECHIN GALLATE; GENISTEIN; ICOSAPENTAENOIC ACID; INTERFERON; KAHWEOL; LYCOPENE; RESVERATROL; RETINOIC ACID; RETINOID; SILYMARIN; SULFORAPHANE; UNCLASSIFIED DRUG; XANTHOHUMOL;

ABSENCE OF SIDE EFFECTS; ADENOMATOUS POLYP; ALZHEIMER DISEASE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HUMAN; ISCHEMIC HEART DISEASE; LEUKOPENIA; LIVER CELL CARCINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STOMACH PROTECTION; THROMBOCYTOPENIA;

EID: 81855212657     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-011-0227-8     Document Type: Review

References (169)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271-85. (Pubitemid 29488770)
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76. (Pubitemid 46890874)
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer. 2006;6: 674-87. (Pubitemid 44286000)
4. Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives. J Gastroenterol. 2010;45:794-807.
5. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37-51. (Pubitemid 350182575)
6. Liu RH. Potential synergy of phytochemicals in cancer prevention: Mechanism of action. J Nutr. 2004;134:3479S-85S. (Pubitemid 39587593)
7. Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin. 2007;28:1343-54. (Pubitemid 47366676)
8. Shu L, Cheung KL, Khor TO, Chen C, Kong AN. Phytochemicals: Cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev. 2010;29:483-502.
9. Damery S, Gratus C, Grieve R, Warmington S, Jones J, Routledge P, et al. The use of herbal medicines by people with cancer: A cross-sectional survey. Br J Cancer. 2011;104:927-33.
10. Hong WK, Lippman SM. Cancer chemoprevention. J Natl Cancer Inst Monogr. 1995:49-53.
11. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: A meta-analysis. J Viral Hepat. 2009;16:265-71.
12. Akuta N, Suzuki F, Suzuki Y, Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, et al. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol. 2005;40:688-96. (Pubitemid 40827531)
13. Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol. 2005;3:S141-3. (Pubitemid 41427747)
14. Suou T, Mitsuda A, Koda M, Matsuda H, Maruyama S, Tanaka H, et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: A pilot study. Hepatol Res. 2001;20:301-11. (Pubitemid 32573892)
15. Uenishi T, Nishiguchi S, Tamori A, Yamamoto T, Shuto T, Hirohashi K, et al. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2006;36:195-200. (Pubitemid 44575933)
16. Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol. 2008;14: 6140-4.
17. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advancedchronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429-41.
18. de Lope CR, Bruix J. Failure of interferon to prevent disease progression and liver cancer in hepatitis C virus infection: Proof of absence or absence of proof? Gastroenterology. 2010;138: 777-9.
19. Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H, Muto Y, et al. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun. 1995;207:382-8.
20. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al. The nuclear receptor superfamily: The second decade. Cell. 1995;83:835-9.
21. Matsushima-Nishiwaki R, Shidoji Y, Nishiwaki S, Yamada T, Moriwaki H, Muto Y. Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma. Mol Cell Endocrinol. 1996;121:179-90. (Pubitemid 26394727)
22. Yanagitani A, Yamada S, Yasui S, Shimomura T, Murai R, Murawaki Y, et al. Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology. 2004;40:366-75. (Pubitemid 39062854)
23. Shimizu M, Sakai H, Shirakami Y, Iwasa J, Yasuda Y, Kubota M, et al. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J- +(db)/ +Lepr(db) mice. Cancer Prev Res (Phila). 2011;4:128-36.
24. Komi Y, Sogabe Y, Ishibashi N, Sato Y, Moriwaki H, Shimokado K, et al. Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab Invest. 2010;90:52-60.
25. Tatsukawa H, Sano T, Fukaya Y, Ishibashi N, Watanabe M, Okuno M, et al. Dual induction of caspase 3- and transglutaminase- dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer. 2011;10:4.
26. Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB, et al. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res. 2002;62: 3997-4006. (Pubitemid 34791066)
27. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996;334:1561-7. (Pubitemid 26177483)
28. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 1999;340:1046-7. (Pubitemid 29157643)
29. Okita K, Matsui O, Kumada H, Tanaka K, Kaneko S, Moriwaki H, et al. Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebocontrolled trial. J Clin Oncol. 2010;28:4024. [abstract].
30. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352: 179-84. (Pubitemid 28327802)
31. Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Tsujimoto T, et al. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Curr Med Chem. 2007;14:2749-54. (Pubitemid 350130918)
32. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol. 2002;37:22-30. (Pubitemid 34713051)
33. Noguchi R, Yoshiji H, Kuriyama S, et al. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res. 2003;9: 6038-45. (Pubitemid 38018091)
34. Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, et al. Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats. Anticancer Res. 2005;25:3335-40. (Pubitemid 41105209)
35. Yoshiji H, Noguchi R, Kaji K, Ikenaka Y, Shirai Y, Namisaki T, et al. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branchedchain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J Gastroenterol. 2010;45:443-50.
36. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29:1675-84.
37. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol. 2009;51:315-21.
38. Bode AM, Dong Z. The enigmatic effects of caffeine in cell cycle and cancer. Cancer Lett. 2007;247:26-39. (Pubitemid 44959418)
39. Nkondjock A. Coffee consumption and the risk of cancer: An overview. Cancer Lett. 2009;277:121-5.
40. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology. 2005;129:1928-36. (Pubitemid 41772970)
41. Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: A case-control study. J Hepatol. 2005;42:528-34. (Pubitemid 40342932)
42. Ohfuji S, Fukushima W, Tanaka T, Habu D, Tamori A, Sakaguchi H, et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A case-control study. Hepatol Res. 2006;36:201-8. (Pubitemid 44575932)
43. Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Coffee consumption and reduced risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. Cancer Causes Control. 2011;22:503-10.
44. Balansky RM, Blagoeva PM, Mircheva ZI, De Flora S. Modulation of diethylnitrosamine carcinogenesis in rat liver and oesophagus. J Cell Biochem. 1994;56:449-54.
45. Hosaka S, Kawa S, Aoki Y, Tanaka E, Yoshizawa K, Karasawa Y, et al. Hepatocarcinogenesis inhibition by caffeine in ACI rats treated with 2-acetylaminofluorene. Food Chem Toxicol. 2001;39:557-61. (Pubitemid 32429468)
46. Asaad NA, Zeng ZC, Guan J, Thacker J, Iliakis G. Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: Reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. Oncogene. 2000;19:5788-800.
47. Wang TJ, Liu ZS, Zeng ZC, Du SS, Qiang M, Zhang SM, et al. Caffeine enhances radiosensitization to orthotopic transplant LM3 hepatocellular carcinoma in vivo. Cancer Sci. 2010;101: 1440-6.
48. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol. 2002;40: 1155-63. (Pubitemid 34626880)
49. Okano J, Nagahara T, Matsumoto K, Murawaki Y. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin Pharmacol Toxicol. 2008;102:543-51. (Pubitemid 351691962)
50. Tao KS, Wang W, Wang L, Cao DY, Li YQ, Wu SX, et al. The multifaceted mechanisms for coffeés anti-tumorigenic effect on liver. Med Hypotheses. 2008;71:730-6.
51. Tai J, Cheung S, Chan E, Hasman D. Antiproliferation effect of commercially brewed coffees on human ovarian cancer cells in vitro. Nutr Cancer. 2010;62:1044-57.
52. Holzer P, Sametz W. Gastric mucosal protection against ulcerogenic factors in the rat mediated by capsaicin-sensitive afferent neurons. Gastroenterology. 1986;91:975-81. (Pubitemid 16023343)
53. Chang HC, Chen ST, Chien SY, Kuo SJ, Tsai HT, Chen DR. Capsaicin may induce breast cancer cell death through apoptosis- inducing factor involving mitochondrial dysfunction. Hum Exp Toxicol. 2011 (in press).
54. Díaz-Laviada I. Effect of capsaicin on prostate cancer cells. Future Oncol. 2010;6:1545-50.
55. Lu HF, Chen YL, Yang JS, Yang YY, Liu JY, Hsu SC, et al. Antitumor activity of capsaicin on human colon cancer cells in vitro and colo 205 tumor xenografts in vivo. J Agric Food Chem. 2010;58:12999-3005.
56. Jung MY, Kang HJ, Moon A. Capsaicin-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downregulation and caspase-3 activation. Cancer Lett. 2001;165:139-45. (Pubitemid 32244170)
57. Baek YM, Hwang HJ, Kim SW, Hwang HS, Lee SH, Kim JA, et al. A comparative proteomic analysis for capsaicin-induced apoptosis between human hepatocarcinoma (HepG2) and human neuroblastoma (SK-N-SH) cells. Proteomics. 2008;8:4748-67.
58. Huang SP, Chen JC, Wu CC, Chen CT, Tang NY, Ho YT, et al. Capsaicin-induced apoptosis in human hepatoma HepG2 cells. Anticancer Res. 2009;29:165-74.
59. Oyagbemi AA, Saba AB, Azeez OI. Capsaicin: A novel chemopreventive molecule and its underlying molecular mechanisms of action. Indian J Cancer. 2010;47:53-8.
60. Thoennissen NH, O'Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, et al. Capsaicin causes cell-cycle arrest and apoptosis in ERpositive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Oncogene. 2010;29:285-96.
61. Yang ZH, Wang XH, Wang HP, Hu LQ, Zheng XM, Li SW. Capsaicin mediates cell death in bladder cancer T24 cells through reactive oxygen species production and mitochondrial depolarization. Urology. 2010;75:735-41.
62. Seubwai W, Vaeteewoottacharn K, Hiyoshi M, Suzu S, Puapairoj A, Wongkham C, et al. Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB. Cancer Sci. 2010;101:1590-5.
63. Harada K, Ferdous T, Itashiki Y, Takii M, Mano T, Mori Y, et al. Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin- 8. Int J Oncol. 2009;35:1025-35.
64. Kikukawa Y, Okuno Y, Tatetsu H, Nakamura M, Harada N, Ueno S, et al. Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid. Int J Oncol. 2008;33:807-14.
65. Biswas KK, Tancharoen S, Sarker KP, Kawahara K, Hashiguchi T, Maruyama I. Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (HuH-7) through the activation of JNK1/2 and the downregulation of Akt. FEBS Lett. 2006;580:703-10. (Pubitemid 43089709)
66. Nakajima A, Yamamoto Y, Taura K, Hata K, Fukumoto M, Uchinami H, et al. Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. Int J Oncol. 2004;24:635-45.
67. Kim SY, Koo YK, Koo JY, Ngoc TM, Kang SS, Bae K, et al. Platelet anti-aggregation activities of compounds from Cinnamomum cassia. J Med Food. 2010;13:1069-74.
68. Subash Babu P, Prabuseenivasan S, Ignacimuthu S. Cinnamaldehyde- a potential antidiabetic agent. Phytomedicine. 2007;14: 15-22.
69. Chew EH, Nagle AA, Zhang Y, Scarmagnani S, Palaniappan P, Bradshaw TD, et al. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: Potential candidates for cancer therapy and chemoprevention. Free Radic Biol Med. 2010;48:98-111.
70. Lee CW, Hong DH, Han SB, Park SH, Kim HK, Kwon BM, et al. Inhibition of human tumor growth by 20-hydroxy- and 20- benzoyloxycinnamaldehydes. Planta Med. 1999;65:263-6. (Pubitemid 29186085)
71. Han DC, Lee MY, Shin KD, Jeon SB, Kim JM, Son KH, et al. 20-benzoyloxycinnamaldehyde induces apoptosis in human carcinoma via reactive oxygen species. J Biol Chem. 2004;279: 6911-20. (Pubitemid 38248834)
72. Wu SJ, Ng LT, Lin CC. Cinnamaldehyde-induced apoptosis in human PLC/PRF/5 cells through activation of the proapoptotic Bcl-2 family proteins and MAPK pathway. Life Sci. 2005;77: 938-51.
73. Moon EY, Lee MR, Wang AG, Lee JH, Kim HC, Kim HM, et al. Delayed occurrence of H-ras12 V-induced hepatocellular carcinoma with long-term treatment with cinnamaldehydes. Eur J Pharmacol. 2006;530:270-5.
74. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 2010;62:1137-41.
75. Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 30-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol. 2007;30:905-18.
76. Cao J, Liu Y, Jia L, Zhou HM, Kong Y, Yang G, et al. Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radic Biol Med. 2007;43:968-75. (Pubitemid 47223632)
77. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D, et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest. 2007;25:411-8. (Pubitemid 47450667)
78. Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin JK, Lai GM, et al. Curcumin-containing diet inhibits diethylnitrosamineinduced murine hepatocarcinogenesis. Carcinogenesis. 2000;21: 331-5. (Pubitemid 30098723)
79. Shukla Y, Arora A. Suppression of altered hepatic foci development by curcumin in Wistar rats. Nutr Cancer. 2003;45:53-9. (Pubitemid 36736892)
80. Sreepriya M, Bali G. Effects of administration of embelin and curcumin on lipid peroxidation, hepatic glutathione antioxidant defense and hematopoietic system during N-nitrosodiethylamine/ phenobarbital-induced hepatocarcinogenesis in Wistar rats. Mol Cell Biochem. 2006;284:49-55. (Pubitemid 44404409)
81. Yoysungnoen P, Wirachwong P, Bhattarakosol P, et al. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc. 2006;34:109-15. (Pubitemid 43351018)
82. Lin LI, Ke YF, Ko YC, Lin JK. Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology. 1998;55: 349-53.
83. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7:1894-900. (Pubitemid 32994823)
84. Shukla Y, Kalra N. Cancer chemoprevention with garlic and its constituents. Cancer Lett. 2007;247:167-81. (Pubitemid 46240620)
85. Block E. The chemistry of garlic and onions. Sci Am. 1985;252: 114-9.
86. Ginter E, Simko V. Garlic (Allium sativum L.) and cardiovascular diseases. Bratisl Lek Listy. 2010;111:452-6.
87. Haber-Mignard D, Suschetet M, Bergès R, Astorg P, Siess MH. Inhibition of aflatoxin B1- and N-nitrosodiethylamine-induced liver preneoplastic foci in rats fed naturally occurring allyl sulfides. Nutr Cancer. 1996;25:61-70. (Pubitemid 26035427)
88. Sengupta A, Ghosh S, Das RK, Bhattacharjee S, Bhattacharya S. Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways. Eur J Cancer Prev. 2006;15: 301-5. (Pubitemid 44060487)
89. Wang HC, Yang JH, Hsieh SC, Sheen LY. Allyl sulfides inhibit cell growth of skin cancer cells through induction of DNA damage mediated G2/M arrest and apoptosis. J Agric Food Chem. 2010;58:7096-103.
90. Singh A, Arora A, Shukla Y. Modulation of altered hepatic foci induction by diallyl sulphide in Wistar rats. Eur J Cancer Prev. 2004;13:263-9. (Pubitemid 39096078)
91. Ibrahim SS, Nassar NN. Diallyl sulfide protects against Nnitrosodiethylamine- induced liver tumorigenesis: Role of aldose reductase. World J Gastroenterol. 2008;14:6145-53.
92. Shaik IH, George JM, Thekkumkara TJ, Mehvar R. Protective effects of diallyl sulfide, a garlic constituent, on the warm hepatic ischemia-reperfusion injury in a rat model. Pharm Res. 2008;25:2231-42.
93. Manerba A, Vizzardi E, Metra M, Dei Cas L. n-3 PUFAs and cardiovascular disease prevention. Future Cardiol. 2010;6: 343-50.
94. Gao L, Wang J, Sekhar KR, Yin H, Yared NF, Schneider SN, et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem. 2007;282:2529-37. (Pubitemid 47076775)
95. Trabal J, Leyes P, Forga M, Maurel J. Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition. Nutr Hosp. 2010;25:736-40.
96. Fini L, Piazzi G, Ceccarelli C, Daoud Y, Belluzzi A, Munarini A, et al. Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min/?) mice. Clin Cancer Res. 2010;16:5703-11.
97. West NJ, Clark SK, Phillips RK, Hutchinson JM, Leicester RJ, Belluzzi A, et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut. 2010;59:918-25.
98. Calviello G, Palozza P, Franceschelli P, Frattucci A, Piccioni E, Tessitore L, et al. Eicosapentaenoic acid inhibits the growth of liver preneoplastic lesions and alters membrane phospholipid composition and peroxisomal beta-oxidation. Nutr Cancer. 1999;34:206-12. (Pubitemid 29511119)
99. Ishii H, Horie Y, Ohshima S, Anezaki Y, Anezaki Y, Kinoshita N, et al. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J Hepatol. 2009;50:562-71.
100. Calviello G, Palozza P, Piccioni E, Maggiano N, Frattucci A, Franceschelli P, et al. Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: Effects on proliferation and apoptosis. Int J Cancer. 1998;75:699-705. (Pubitemid 28145816)
101. Notarnicola M, Messa C, Refolo MG, Tutino V, Miccolis A, Caruso MG. Polyunsaturated fatty acids reduce fatty acid synthase and hydroxy-methyl- glutaryl CoA-reductase gene expression and promote apoptosis in HepG2 cell line. Lipids Health Dis. 2011;10:10.
102. Lim K, Han C, Dai Y, Shen M, Wu T. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther. 2009;8:3046-55.
103. Yang CS, Lambert JD, Ju J, Lu G, Sang S. Tea and cancer prevention: Molecular mechanisms and human relevance. Toxicol Appl Pharmacol. 2007;224:265-73. (Pubitemid 47592860)
104. Yang CS, Wang H, Li GX, Yang Z, Guan F, Jin H. Cancer prevention by tea: Evidence from laboratory studies. Pharmacol Res. 2011. doi:10.1016/j.phrs.2011. 03.001.
105. Chen D, Daniel KG, Kuhn DJ, Kazi A, Bhuiyan M, Li L, et al. Green tea and tea polyphenols in cancer prevention. Front Biosci. 2004;9:2618-31.
106. Yamane T, Takahashi T, Kuwata K, Oya K, Inagake M, Kitao Y, et al. Inhibition of N-methyl-N0-nitro-N-nitrosoguanidineinduced carcinogenesis by (-)-epigallocatechin gallate in the rat glandular stomach. Cancer Res. 1995;55:2081-4.
107. Matsumoto N, Kohri T, Okushio K, Hara Y. Inhibitory effects of tea catechins, black tea extract and oolong tea extract on hepatocarcinogenesis in rat. Jpn J Cancer Res. 1996;87: 1034-8. (Pubitemid 26392039)
108. Umemura T, Kai S, Hasegawa R, Kanki K, Kitamura Y, Nishikawa A, et al. Prevention of dual promoting effects of pentachlorophenol, an environmental pollutant, on diethylnitrosamine- induced hepato- and cholangiocarcinogenesis in mice by green tea infusion. Carcinogenesis. 2003;24:1105-9. (Pubitemid 36827263)
109. Shimizu M, Sakai H, Shirakami Y, Yasuda Y, Kubota M, Terakura D, et al. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Prev Res (Phila). 2011;4:396-403.
110. Kaufmann R, Henklein P, Henklein P, Settmacher U. Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation. Oncol Rep. 2009;21:1261-7.
111. Nishikawa T, Nakajima T, Moriguchi M, Jo M, Sekoguchi S, Ishii M, et al. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J Hepatol. 2006;44:1074-82.
112. Huang CH, Tsai SJ, Wang YJ, Pan MH, Kao JY, Way TD. EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol Nutr Food Res. 2009;53: 1156-65.
113. Shirakami Y, Shimizu M, Adachi S, Sakai H, Nakagawa T, Yasuda Y, et al. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci. 2009; 100:1957-62.
114. Rusin A, Krawczyk Z, Grynkiewicz G, Gogler A, Zawisza-Puchalka J, Szeja W. Synthetic derivatives of genistein, their properties and possible applications. Acta Biochim Pol. 2010;57:23-34.
115. Sharp GB, Lagarde F, Mizuno T, Sauvaget C, Fukuhara T, Allen N, et al. Relationship of hepatocellular carcinoma to soya food consumption: A cohort-based, case-control study in Japan. Int J Cancer. 2005;115:290-5. (Pubitemid 40586739)
116. Lei B, Roncaglia V, Viganò R, Cremonini C, De Maria N, Del Buono MG, et al. Phytoestrogens and liver disease. Mol Cell Endocrinol. 2002;193:81-4. (Pubitemid 34823610)
117. Fukuda K, Shibata A, Hirohata I, Tanikawa K, Yamaguchi G, Ishii M. A hospital-based case-control study on hepatocellular carcinoma in Fukuoka and Saga Prefectures, northern Kyushu, Japan. Jpn J Cancer Res. 1993;84:708-14. (Pubitemid 23230273)
118. Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S, et al. Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. Int J Cancer. 2009;124: 1644-9.
119. Su SJ, Chow NH, Kung ML, Hung TC, Chang KL. Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl- 2 and Bcl-XL downregulation, and Cdc2 kinase activity. Nutr Cancer. 2003;45:113-23.
120. Jin CY, Park C, Moon SK, Kim GY, Kwon TK, Lee SJ, et al. Genistein sensitizes human hepatocellular carcinoma cells toTRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs. 2009;20:713-22.
121. Chodon D, Banu SM, Padmavathi R, Sakthisekaran D. Inhibition of cell proliferation and induction of apoptosis by genistein in experimental hepatocellular carcinoma. Mol Cell Biochem. 2007;297:73-80. (Pubitemid 46443531)
122. Ji G, Yang Q, Hao J, Guo L, Chen X, Hu J, et al. Antiinflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol. 2011;11:762-8.
123. Seren S, Mutchnick M, Hutchinson D, Harmanci O, Bayraktar Y, Mutchnick S, et al. Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma. Nutr Cancer. 2008;60:729-35.
124. Burton GW, Ingold KU. beta-Carotene: An unusual type of lipid antioxidant. Science. 1984;224:569-73. (Pubitemid 14137524)
125. Lippi G, Targher G. Tomatoes, lycopene-containing foods and cancer risk. Br J Cancer. 2011;104:1234-5.
126. Chew BP, Park JS. Carotenoid action on the immune response. J Nutr. 2004;134:257S-61S. (Pubitemid 38057459)
127. Gius D, Botero A, Shah S, Curry HA. Intracellular oxidation/ reduction status in the regulation of transcription factors NFkappaB and AP-1. Toxicol Lett. 1999;106:93-106. (Pubitemid 29257819)
128. Polívková Z, Šmerák P, Demová H, HouŠka M. Antimutagenic effects of lycopene and tomato purée. J Med Food. 2010;13: 1443-50.
129. Astorg P, Gradelet S, Bergès R, Suschetet M. Dietary lycopene decreases the initiation of liver preneoplastic foci by diethylnitrosamine in the rat. Nutr Cancer. 1997;29:60-8. (Pubitemid 27508126)
130. Toledo LP, Ong TP, Pinho AL, Jordao A Jr, Vanucchi H, Moreno FS. Inhibitory effects of lutein and lycopene on placental glutathione S-transferase-positive preneoplastic lesions and DNA strand breakage induced in Wistar rats by the resistant hepatocyte model of hepatocarcinogenesis. Nutr Cancer. 2003;47: 62-9. (Pubitemid 38250437)
131. Nishino H. Prevention of hepatocellular carcinoma in chronic viral hepatitis patients with cirrhosis by carotenoid mixture. Recent Results Cancer Res. 2007;174:67-71.
132. Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis- promoted hepatocarcinogenesis in rats. Int J Cancer. 2010;126:1788-96.
133. Chachay VS, Kirkpatrick CM, Hickman IJ, Ferguson M, Prins JB, Martin JH. Resveratrol-pills to replace a healthy diet? Br J Clin Pharmacol. 2011. doi:10.1111/j.1365-2125. 2011.03966.x.
134. Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: Inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact. 2009;179:131-44.
135. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 2004;24:2783-840. (Pubitemid 39409568)
136. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: Molecular mechanisms and therapeutic potential. Front Biosci. 2007;12:4839-54.
137. Vitrac X, Desmoulière A, Brouillaud B, Krisa S, Deffieux G, Barthe N, et al. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 2003;72:2219-33. (Pubitemid 36292144)
138. Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, Chatterjee M, et al. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res. 2010;27:1080-91.
139. Delmas D, Jannin B, Cherkaoui Malki M, Latruffe N. Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol Rep. 2000;7:847-52.
140. Notas G, Nifli AP, Kampa M, Vercauteren J, Kouroumalis E, Castanas E. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta. 2006;1760: 1657-66. (Pubitemid 44667277)
141. Yu H, Pan C, Zhao S, Wang Z, Zhang H, Wu W. Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase- 9 expression and invasion of human hepatocellular carcinoma cells. Biomed Pharmacother. 2008;62:366-72. (Pubitemid 351899097)
142. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: Past, present, future. Phytother Res. 2010;24: 1423-32.
143. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases-a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. 2005;100: 2583-91.
144. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, et al. Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2008;47:605-12. (Pubitemid 351280729)
145. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269:352-62.
146. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105-13. (Pubitemid 19181371)
147. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010;50:434-49.
148. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, et al. Silymarin use and liver disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Aliment Pharmacol Ther. 2011;33:127-37.
149. Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, et al. Silymarin inhibited proliferation and induced apoptosis in
150. Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol. 2007;13: 5299-305. (Pubitemid 47559458)
151. Momeny M, Khorramizadeh MR, Ghaffari SH, Yousefi M, Yekaninejad MS, Esmaeili R, et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol. 2008;591:13-20.
152. Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res. 2005;11:8441-8. (Pubitemid 41746959)
153. Wu YF, Fu SL, Kao CH, Yang CW, Lin CH, Hsu MT, et al. Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res. 2008;68:2033-42.
154. Ramakrishnan G, Augustine TA, Jagan S, Vinodhkumar R, Devaki T. Effect of silymarin on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Exp Oncol. 2007;29:39-44. (Pubitemid 46713478)
155. Bonifaz V, Shan Y, Lambrecht RW, Donohue SE, Moschenross D, Bonkovsky HL. Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int. 2009;29:366-73.
156. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, et al. Silibinin and related compounds aredirect inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. 2010;138:1112-22.
157. Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett. 2008;269:291-304.
158. Pappa G, Strathmann J, Löwinger M, Bartsch H, Gerhäuser C. Quantitative combination effects between sulforaphane and 3,30- diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis. 2007;28:1471-7. (Pubitemid 47241796)
159. Park SY, Kim GY, Bae SJ, et al. Induction of apoptosis by isothiocyanate sulforaphane in human cervical carcinoma HeLa and hepatocarcinoma HepG2 cells through activation of caspase- 3. Oncol Rep. 2007;18:181-7.
160. Yeh CT, Yen GC. Effect of sulforaphane on metallothionein expression and induction of apoptosis in human hepatoma HepG2 cells. Carcinogenesis. 2005;26:2138-48.
161. Moon DO, Kang SH, Kim KC, Kim MO, Choi YH, Kim GY. Sulforaphane decreases viability and telomerase activity in hepatocellular carcinoma Hep3B cells through the reactive oxygen species-dependent pathway. Cancer Lett. 2010;295: 260-6.
162. Cho SD, Li G, Hu H, Jiang C, Kang KS, Lee YS, et al. Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells. Nutr Cancer. 2005;52:213-24. (Pubitemid 41579763)
163. Shen G, Xu C, Chen C, Hebbar V, Kong AN. p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol. 2006;57:317-27.
164. Hu C, Eggler AL, Mesecar AD, van Breemen RB. Modification of Keap1 cysteine residues by sulforaphane. Chem Res Toxicol. 2011;24:515-21.
165. Lee IS, Lim J, Gal J, Kang JC, Kim HJ, Kang BY, et al. Antiinflammatory activity of xanthohumol involves heme oxygenase- 1 induction via NRF2-ARE signaling in microglial BV2 cells. Neurochem Int. 2011;58:153-60.
166. Deeb D, Gao X, Jiang H, Arbab AS, Dulchavsky SA, Gautam SC. Growth inhibitory and apoptosis-inducing effects of xanthohumol, a prenylated chalone present in hops, in human prostate cancer cells. Anticancer Res. 2010;30:3333-9.
167. Ho YC, Liu CH, Chen CN, Duan KJ, Lin MT. Inhibitory effects of xanthohumol from hops (Humulus lupulus L.) on human hepatocellular carcinoma cell lines. Phytother Res. 2008;22: 1465-8.
168. Dorn C, Weiss TS, Heilmann J, Hellerbrand C. Xanthohumol, a prenylated chalcone derived from hops, inhibits proliferation, migration and interleukin-8 expression of hepatocellular carcinoma cells. Int J Oncol. 2010;36:435-41.
169. Ferk F, Huber WW, Filipic M, Bichler J, Haslinger E, Misík M, et al. Xanthohumol, a prenylated flavonoid contained in beer, prevents the induction of preneoplastic lesions and DNA damage in liver and colon induced by the heterocyclic aromatic amine amino-3-methyl-imidazo[4,5-f]quinoline (IQ). Mutat Res. 2010;691:17-22.